Royal Philips | November 28, 2022
Royal Philips a global leader in health technology announced its portfolio of smart diagnostic systems and transformative workflow solutions featured at the Radiological Society of North America annual meeting. Powered by AI, the company will showcase its latest systems and informatics solutions designed for providers to efficiently deliver patient-centric, high-quality imaging services.
Overwhelming volume of radiology data compounding staff shortages and burnout
Radiology plays a critical role in diagnosing and guiding patients into the right treatment plans. However, with increasing staff shortages and workloads, radiologists and staff continue to struggle to manage and interpret the huge volume of data captured to provide quality care for each patient. In the recent Future Health Index 2022 report commissioned by Philips, 24% of radiology leaders surveyed stated that managing the sheer volume of data available to them is their top data-related issue, with nearly two-thirds (65%) indicating their staff are overwhelmed by data overload.
“With 47% of radiologists experiencing burnout , our customers are looking for innovations to help reduce their workloads and seamlessly integrate into their day-to-day operations. With smart intelligence built into imaging systems and informatics across the radiology workflow, Philips’ integrated solutions condense large volumes of data into patient-centric actionable insights for earlier and more definitive diagnosis and treatment.”
Kees Wesdorp, Chief Business Leader of Precision Diagnosis at Philips
AI-powered solutions enhance operational efficiencies and simplify complex workflows
Some of the biggest challenges facing radiology leaders today are driven by managing complex, disconnected workflows which can negatively impact patient care, staff experience, outcomes, and cost. Visitors to the Philips booth at RSNA will see how the company’s latest interoperable and vendor-neutral operational solutions and strong portfolio of smart connected imaging systems help streamline and transform the radiology workflow to improve patient and staff experience; advance clinical and diagnostic confidence for better health outcomes; and drive a sustainable, resilient diagnostic infrastructure to help lower the cost of care. Featured at RSNA will be Philips’ AI-enabled technology  that automates and accelerates routine and repetitive tasks to generate patient-centric insights from large volumes of data to help improve productivity.
Solutions include Philips Imaging Orchestrator – ROCC and Philips Ultrasound Collaboration Live, both pioneering the virtualization of radiology, extending care and collaboration beyond traditional models. Philips Imaging Orchestrator – ROCC, a vendor-neutral, multi-modality, multi-site telepresence solution provides advanced tele-acquisition capabilities and seamlessly connects imaging experts at a command center with technologists at scanning locations across an organization. Philips Ultrasound Collaboration Live tele-ultrasound, available on Philips ultrasound systems – EPIQ Elite and Affiniti – allows teams to securely video stream from their ultrasound system to a PC or mobile device for remote, on-demand access to clinical expertise regardless of location.
Philips will also introduce the latest in AI-enabled image interpretation to help prioritize patient worklists based on clinical outcomes and expand diagnostic capabilities with its new Philips Advanced Visualization Workspace, with enhanced features to automate reporting and help drive earlier and more definitive diagnosis. Also featured is Philips Enterprise Performance Analytics – PerformanceBridge – to enhance operational decision-making through a vendor-neutral, real-time data analysis solution to help improve productivity and reduce costs.
Smart connected imaging systems advance clinical and diagnostic confidence
New at RSNA, Philips’ AI-powered MR SmartSpeed is designed to increase speed, image quality, and productivity and drive diagnostic confidence with improved image resolution via the AI reconstruction algorithm. It utilizes Philips’ state-of-the-art speed engine and an award-winning  AI reconstruction technology delivered at the source of the MR signal to ensure no data loss. SmartSpeed joins the company’s expanding portfolio of AI-driven MR solutions which includes AI-based touchless patient sensing, SmartExam, and MR Workspace. Philips will also showcase MR 5300, Philips’ newest BlueSeal Magnet, and industry-first wide bore helium-free operations system design for sustainable imaging at lower site costs without image quality or clinical compromises.
Philips will spotlight its award-winning Spectral CT 7500, the company’s latest dual-detector CT system helping radiologists better characterize disease and reduce scan times at the same dose levels as conventional scans. Used in oncology imaging, cardiac imaging, and interventional radiology, the system has demonstrated a 34% reduction in time to diagnosis, a 25% reduction in repeat scans and a 30% reduction in follow-up scans . Philips will also demonstrate its latest innovations in minimally-invasive care with the company’s SmartCT 3D suite of interventional tools including its Azurion 7 C20 with FlexArm Image-Guided Therapy System and Zenition 70 Mobile C-arm with Flat Detector.
Philips will also introduce the Ultrasound Compact 5000 Series system and the Philips Lumify Handheld Ultrasound, now featuring pulse wave Doppler for all physicians – from cardiologists and radiologists to emergency care – to quickly assess hemodynamics in cardiac function anytime, anywhere. Also making its first appearance at RSNA is Philips Fluoroscopy 7000 N – ProxiDiagnost N90, combining digital radiography and high-end nearby fluoroscopy to help enhance clinical confidence and improve patient and staff satisfaction.
About Royal Philips
Royal Philips is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries.
Canon Medical Systems USA | November 28, 2022
Canon Inc. announced that the company has decided to establish a new subsidiary, to be named Canon Healthcare USA, INC. By strengthening its presence in the highly influential American medical market, Canon aims to accelerate the growth of its medical business.
The Canon group is currently working towards a grand strategic transformation of its business portfolio in order to realize future growth. With the announcement of Phase VI, the latest in the company’s Excellent Global Corporation Plan series of 5-year management programs, Canon’s primary objective is to “thoroughly strengthen business competitiveness.” Under this slogan, Canon is striving to increase its competitiveness in various spheres of the medical industry, including diagnostics such as CT, MRI, diagnostic ultrasound systems, as well as medical component businesses such as X-ray tubes, X-ray detectors and key MRI components. In addition, the company is making strides in the field of healthcare IT and in vitro diagnostics.
One of the most pressing challenges for Canon’s medical business has been the need to strengthen its presence in the American medical industry, which is extremely influential on the global market. Canon has decided to consider the greater Cleveland area, a key hub in the country’s medical industry as a candidate location for establishing Canon Healthcare USA, INC. in order to strengthen the company’s competitive presence in the global market.
With the establishment of Canon Healthcare USA, INC., Canon will transfer a portion of its marketing operations, incubated at the Global Headquarters over Canon’s long history. These operations will transfer to the Global Marketing Center, to be established in January of 2023, in order to strengthen upstream marketing1. By establishing a network with medical institutions on the front lines of treatment and achieving a greater understanding of the market, Canon will develop and propose products and solutions that address the trends and needs of the medical market. Among such efforts is the commencement of joint research with American medical institutions on the practical application of X-ray CT systems utilizing photon counting detection modules, with the goal of capturing the No.1 share of the global CT market at an early stage.
In addition, Canon Medical Systems USA the U.S. subsidiary of Canon Medical Systems Corporation will transfer a portion of its product sales and service operations to Canon Healthcare USA. This will integrate operations with downstream marketing2, thereby enabling the company to focus on increasing its share of medical diagnostic systems in the American market.
The Cleveland area, one of the candidate locations, is home to the headquarters and factory of Quality Electrodynamics, LLC which develops and manufactures MRI key components and was welcomed into the Canon Group in 2019. By placing QED under the umbrella of Canon Healthcare USA, Canon will aim to increase coordination between its system and component businesses.
Furthermore, Canon Medical will take over the advanced technology research activities that Canon has been conducting with Massachusetts General Hospital and Brigham Women’s Hospital at the Healthcare Optics Research Laboratory in Boston for 10 years, and will promote joint research aimed at commercialization in collaboration with the Global Marketing Center. In addition, Canon is considering the possibility of expanding U.S.-based development, manufacturing and other capabilities, with the goal of further strengthening its business in the country.
The establishment of this new company and expansion of business operations is expected to require USD $300 million of investment capital. This investment will empower Canon’s medical business to grow by deepening its understanding of customer and market needs, as well as redouble its efforts in the American market, thereby contributing to the global medical industry.
ASEP Medical Holdings Inc | November 25, 2022
Asep Medical Holdings Inc. is pleased to announce that, for recruitment, incentivization, and retention purposes, it has granted to certain officers and advisors an aggregate of 1,080,000 stock options to purchase up to 1,080,000 common shares of the Company of which 200,000 are exercisable at a price of $0.30 per Share until September 29, 2032, 200,000 are exercisable at a price of $0.30 per share until October 1, 2032, and 680,000 are exercisable at a price of $0.30 per share until November 24, 2032.
ABOUT ASEP MEDICAL HOLDINGS INC
Asep Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections.
Sepset Biosciences Inc. is developing a diagnostic technology that involves a patient gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for nearly 20% of all deaths on the planet. The semester test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling diagnosis of severe sepsis within 1-2 hours of first clinical presentation while other diagnostics only provide diagnosis after 24-36 hours. Asep Inc. believes this will enable critical early decisions to be made by physicians regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis.
ABT Innovations Inc.'s peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections anti-inflammatories, anti-infective immune modulators, and vaccine adjuvants.